Study S002153

A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01064687
Acronym: AWARD-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 978
Start: 2010-02
Primary completion: 2011-11
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY2189265; DRUG:Exenatide; DRUG:Placebo; DRUG:Metformin; DRUG:Pioglitazone
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDA

Registered primary outcomes

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008191	Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Ferdinand KC, Cardiovascular diabetology	2023	Systematic review	PMID 36894938 DOI	cites ClinicalTrials.gov:NCT01064687; registry reference DERIVED:36894938
R0020285	Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M, Diabetes, obesity & metabolism	2016	Other trial	PMID 26691396 DOI	cites ClinicalTrials.gov:NCT01064687; registry reference DERIVED:26691396
R0025090	Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Boustani MA, Diabetes, obesity & metabolism	2016	Other trial	PMID 27161178 DOI	cites ClinicalTrials.gov:NCT01064687; registry reference DERIVED:27161178